Clinical Trials in Leeds, UK | Priya Life Science

Clinical Trials in Leeds

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Status

Study

Lead sponsor

Phase

Enrol

UK sites

Start

Active, closed

A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

NCT03328273Chronic Lymphocytic Leukemia

Acerta Pharma BV

Phase 1

Birmingham, Bournemouth, Cardiff, Leeds, London, Nottingham, Oxford, Southampton

2018-01-31

Active, closed

A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy

NCT02717611Chronic Lymphocytic Leukemia

Acerta Pharma BV

Phase 2

Bournemouth, Leeds, Manchester

2016-03-08

Active, closed

Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)

NCT02477696Chronic Lymphocytic Leukemia

Acerta Pharma BV

Phase 3

533

Birmingham, Bournemouth, Cambridge, Cardiff, Greater London, Hull, Leeds, Leicester

2015-07-28

Active, closed

Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL

NCT02475681Chronic Lymphocytic Leukemia

Acerta Pharma BV

Phase 3

535

Bournemouth, Cambridge, Leeds, Leicester, London, Plymouth, Southampton, Truro

2015-06-26

Active, closed

An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma

NCT02213926Mantle Cell Lymphoma (MCL)

Acerta Pharma BV

Phase 2

124

Cardiff, Leeds, Leicester, Nottingham, Oxford, Plymouth, Southampton

2015-03-02

Active, closed

An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia

NCT02180724Waldenström Macroglobulinemia (WM)

Acerta Pharma BV

Phase 2

107

Bournemouth, Leeds, Leicester, London, Oxford, Plymouth, Southampton

2014-09-11

Active, closed

ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia

NCT02029443Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Richter's Syndrome, Prolymphocytic Leukemia

Acerta Pharma BV

Phase 1/2

306

Leeds, London, Oxford

2014-01-30

Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 20 September 2026. https://priyalifescience.com/clinical-trials-uk/city/leeds

Query this register directly

GET /api/trials?country=uk&status=recruiting&format=json Try it now →